中文名稱:C9抗體 | 英文名稱:Rabbit Monoclonal C9 Antibody |
品牌: 艾普蒂 | 產地: 武漢 |
保存條件: Stored at -20°C for 7812 year. Avoid repeated freeze / thaw cycles. | 產品類別: 抗體 |
重組: 否 | 應用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
種屬反應性: Human,Mouse,Rat | 宿主: Rabbit |
偶聯(lián)物: 無 | 靶點: C9 |
WB | 咨詢技術 | Human,Mouse,Rat |
IF | 1/20-1/50 | Human,Mouse,Rat |
IHC | 1/100-1/200 | Human,Mouse,Rat |
ICC | 技術咨詢 | Human,Mouse,Rat |
FCM | 咨詢技術 | Human,Mouse,Rat |
Elisa | 咨詢技術 | Human,Mouse,Rat |
Aliases | Complement component C9; Comple Complement component C9bment component C9a;;Complement C9 |
WB Predicted band size | Calculated MW: 63 kDa ; Observed MW: 70 kDa |
Host/Isotype | Rabbit IgG |
Antibody Type | Primary antibody |
Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
Species Reactivity | Human |
Immunogen | A synthesized peptide derived from human Complement C9 |
Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
Western blot analysis of C9 expression in Human fetal liver lysate.
Immunohistochemical analysis of paraffin-embedded human kidney, using C9 Antibody.
以下是關于C9抗體的3篇代表性文獻的簡要總結(基于公開領域知識模擬,非真實文獻):
---
1. **文獻名稱**:*"Complement C9 Deposition in Glomeruli of Patients with Membranoproliferative Glomerulonephritis"*
**作者**:Daha, M.R. et al.
**摘要**:研究探討了補體C9在膜增生性腎小球腎炎(MPGN)患者腎組織中的沉積模式,發(fā)現(xiàn)C9抗體可作為疾病活動性的生物標志物,其沉積程度與腎損傷嚴重性相關。
2. **文獻名稱**:*"Anti-C9 Antibodies Block the Formation of the Membrane Attack Complex in Autoimmune Neuropathy"*
**作者**:Halstead, S.K. et al.
**摘要**:通過體外實驗證明,特異性C9抗體可抑制補體膜攻擊復合物(MAC)的組裝,減少神經細胞損傷,為治療吉蘭-巴雷綜合征等自身免疫性神經疾病提供潛在策略。
3. **文獻名稱**:*"Development of a High-Sensitivity ELISA for Detection of C9 Autoantibodies in Neurological Disorders"*
**作者**:Smith, J. & Zhang, Y.
**摘要**:開發(fā)了一種新型ELISA檢測方法,用于定量檢測患者血清中的C9自身抗體,驗證其在多發(fā)性硬化癥和視神經脊髓炎中的診斷價值。
---
**說明**:以上文獻為模擬示例,真實文獻需通過PubMed、Google Scholar等平臺檢索關鍵詞(如 "C9 antibody" "complement C9" "membrane attack complex")。經典研究可參考:
- Podack, E.R. (1984) 對補體C9蛋白結構的早期解析。
- Müller-Eberhard, H.J. (1986) 對補體膜攻擊復合物(MAC)形成的機制研究。
The C9 antibody primarily targets the ninth component (C9) of the complement system, a critical part of innate immunity. The complement cascade, including the membrane attack complex (MAC), plays roles in pathogen elimination and immune regulation. C9 is essential for MAC assembly, forming pores in pathogen membranes to induce lysis. Dysregulated MAC activity, however, contributes to tissue damage in autoimmune and inflammatory diseases, such as glomerulonephritis and age-related macular degeneration.
C9 antibodies are research tools used to study MAC formation, inhibition, and its pathological roles. In neurodegenerative disorders like ALS and frontotemporal dementia (FTD), C9orf72 gene mutations produce toxic dipeptide repeats, triggering neuroinflammation via complement activation, including C9-mediated MAC deposition. C9 antibodies help detect MAC in tissues or block its activity in experimental models, aiding therapeutic development.
Recent studies explore C9 antibodies as potential therapeutics to mitigate MAC-driven damage. Challenges include balancing complement inhibition with host defense preservation. Ongoing research focuses on antibody specificity, delivery to target tissues (e.g., the brain), and optimizing pharmacokinetics. These efforts aim to translate C9-targeted strategies into clinical applications for complement-mediated diseases.
成立日期 | 2024-07-02 (2年) | 注冊資本 | 20萬人民幣 |
員工人數(shù) | 1-10人 | 年營業(yè)額 | ¥ 100萬以內 |
主營行業(yè) | 抗體,蛋白組學,細胞生物學 | 經營模式 | 貿易,工廠,試劑,定制,服務 |
產品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
沈陽萬騰生物科技有限公司
|
2025-08-03 | ||
¥220 |
常州市祥泰生物技術有限公司
|
2025-08-03 | ||
¥1200 |
上海聯(lián)碩寶為生物科技有限公司
|
2025-08-03 | ||
¥4207.50 |
北京孚博生物科技有限公司
|
2025-08-02 | ||
詢價 |
武漢益普生物科技有限公司
|
2022-02-22 |